Kratom Compliance & Quality Systems

Kratom (Mitragyna speciosa) sits in one of the most fragmented regulatory positions in the US consumer-products market, and that fragmentation — not the botany — is the compliance challenge.

The federal position is unusual. Kratom leaf is not a federally controlled substance, but the FDA has not approved it for any use and has objected to its marketing as a dietary supplement or with therapeutic claims. Import alerts have been used against shipments. So a business can operate lawfully at the federal level while having no approved pathway to make claims about its product.

The state picture is where the real complexity lives. Roughly nine states prohibit kratom outright, while 18 or more have adopted a Kratom Consumer Protection Act (KCPA) — model legislation that permits sale subject to conditions on labelling, age restriction, purity and alkaloid content. Others have no specific framework at all, and a growing number of counties and municipalities have imposed local restrictions in the absence of state rules. The direction of travel is toward regulation rather than prohibition — Rhode Island reversed its ban in favour of a regulated framework effective April 2026 — but the map remains genuinely patchwork.

The practical consequence: your compliance obligations are determined by where you sell, and they differ materially between neighbouring states.

This area is moving quickly. Verify the current position before relying on any date below.

The most significant recent change concerns 7-hydroxymitragynine (7-OH), a minor alkaloid present in trace amounts in natural kratom leaf but which can be concentrated or synthesized to produce far more potent products.

In July 2026 the DEA moved to schedule concentrated 7-OH federally for the first time. Notices were published in the Federal Register on July 6, 2026, and a 30-day waiting period applies before a temporary scheduling order can issue — meaning the earliest effective date is early August 2026. A temporary order would run two years, with a possible one-year extension, while permanent scheduling is pursued.

The distinction that matters commercially: the underlying HHS scheduling recommendation targets synthetic and concentrated 7-OH products — not natural kratom leaf or traditional leaf-based preparations. Meanwhile, most KCPA states already regulate rather than ban 7-OH, commonly capping it at 2% of total alkaloids.

If you produce or distribute concentrated 7-OH products, this is an immediate matter requiring legal advice, not a consulting question. If you produce traditional leaf products, the practical implication is that your alkaloid testing and specification control is now the thing that demonstrates which category you are in — and that is squarely a quality-system problem.

It is a fit for:

• Importers of raw kratom leaf and powder
• Processors, blenders and extractors
• Packagers and private-label manufacturers
• Brands and distributors selling across multiple states
• Retailers needing supplier assurance and product documentation
• Manufacturers seeking to meet KCPA requirements in the states they sell into
• Businesses pursuing third-party GMP verification, such as the American Kratom Association's programme

The most common trigger is expansion. A business selling in two states adds a third and discovers the labelling, age-restriction, testing and alkaloid-limit requirements are different — and that its single product specification cannot satisfy all three.

The regulatory landscape is not something a consultant can simplify. What we can do is build a quality system rigorous enough to satisfy the strictest jurisdiction you sell into, and documented well enough to prove it. That is usually the most efficient strategy: one system built to the highest applicable bar rather than a different approach per state.

• Jurisdiction mapping — where you sell, what each state and locality requires, and where you cannot sell
• A GMP-based quality system — built on food and dietary-supplement GMP discipline, since that is the closest applicable framework
• Supplier qualification for imported raw material, including country-of-origin and processing controls
• Testing programme — alkaloid profile including mitragynine and 7-OH content, plus heavy metals, microbial contamination including Salmonella, pesticides and adulterants. Contamination has been the source of the industry's most serious incidents, including multi-state Salmonella outbreaks.
• Specification control — defined alkaloid limits per market, with release testing against them
• Labelling compliance — KCPA labelling and disclosure content, age restrictions, and avoiding therapeutic claims that create FDA exposure
• Traceability and lot control, with a tested recall capability
• Change control — because a supplier or process change can move a product across an alkaloid threshold
• Records and training

We bring 30+ years of building quality systems, 900+ organizations certified, and directly relevant experience in food safety, dietary-supplement GMP, HARPC and hemp and cannabis compliance — another sector where a patchwork of state rules sits on top of an unsettled federal position.

We start with jurisdiction mapping, because it determines everything: which states you can sell in, what each requires, and what your product specification must therefore be. Then we build a GMP-based system to the strictest applicable standard, establish the testing programme and specifications — with alkaloid and 7-OH content treated as a controlled specification rather than an incidental result — and put traceability, labelling control and change control in place.

We are straightforward about two limits. First, we are consultants, not counsel: the legality of a specific product in a specific state, and anything touching the 7-OH scheduling action, needs a regulatory attorney, and we will say so. Second, no quality system makes a prohibited product lawful. What it does is let you operate credibly where you are permitted to operate, document that position, and adapt quickly when a state changes its rules — which, in this sector, they do.

Scope and timeline depend on your products and target states.

• Assuming a single product specification can serve every state when alkaloid limits and labelling requirements differ
• Shipping into states where the product is prohibited, or into localities with restrictions the state has not imposed
• Treating 7-OH content as an incidental test result rather than a controlled specification with market-specific limits
• Making therapeutic or structure-function claims, which is the fastest route to FDA enforcement
• No contamination testing programme — heavy metals, Salmonella and adulterants have caused the industry's most damaging incidents
• Inadequate supplier qualification for imported raw material, where processing conditions are unverified
• No traceability or lot control, making a targeted recall impossible
• No change control, so a supplier switch moves a product across an alkaloid threshold unnoticed
• Missing age-restriction and labelling obligations under applicable KCPA statutes
• Assuming the federal position is settled — it is actively changing